Eisai Co., Ltd. (ESALF)
OTCMKTS · Delayed Price · Currency is USD
26.76
+1.74 (6.50%)
Feb 10, 2026, 9:30 AM EST
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
$472,167
Profits / Employee
$24,979
Market Cap
8.84B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 10,917 | -150 | -1.36% |
| Mar 31, 2024 | 11,067 | -9 | -0.08% |
| Mar 31, 2023 | 11,076 | -246 | -2.17% |
| Mar 31, 2022 | 11,322 | 85 | 0.76% |
| Mar 31, 2021 | 11,237 | 239 | 2.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jushi Holdings | 1,234 |
| MariMed | 832 |
| Glass House Brands | 374 |
| Earth Science Tech | 76 |
| Elite Pharmaceuticals | 68 |
| Radnostix | 42 |
| Healthy Extracts | 2 |
Eisai News
- 5 days ago - Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump - Benzinga
- 5 days ago - Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships - South China Morning Post
- 6 days ago - Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan - PRNewsWire
- 6 days ago - Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters
- 17 days ago - FDA Accepts To Priority Review Eisai And Biogen's LEQEMBI SBLA For Early Alzheimer's Disease - Nasdaq
- 17 days ago - FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector - Nasdaq
- 17 days ago - FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga
- 17 days ago - FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Benzinga